These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 26616335)

  • 1. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
    Vaziri ND; Kalantar-Zadeh K; Wish JB
    Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
    Gupta A; Lin V; Guss C; Pratt R; Ikizler TA; Besarab A
    Kidney Int; 2015 Nov; 88(5):1187-94. PubMed ID: 26154926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
    Fishbane SN; Singh AK; Cournoyer SH; Jindal KK; Fanti P; Guss CD; Lin VH; Pratt RD; Gupta A
    Nephrol Dial Transplant; 2015 Dec; 30(12):2019-26. PubMed ID: 26175145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.
    Pratt RD; Grimberg S; Zaritsky JJ; Warady BA
    Pediatr Nephrol; 2018 Nov; 33(11):2151-2159. PubMed ID: 30003313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.
    Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV
    Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
    Shah HH; Hazzan AD; Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.
    Fishbane S; Shah HH
    Hemodial Int; 2017 Jun; 21 Suppl 1():S104-S109. PubMed ID: 28371161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
    Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M
    Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized anemia management enhanced by ferric pyrophosphate citrate protocol.
    Chait Y; Nathanson BH; Germain MJ
    Sci Rep; 2022 Nov; 12(1):20122. PubMed ID: 36418453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M; Hojs N; Premru V
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.